Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Abstract Background This study compared hospital admission rates among adult patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine. Methods This retrospective cohort study used U.S.-based Truven Health MarketScan® Medicaid Multi-State Database (April 201...

Full description

Bibliographic Details
Main Authors:	John W. Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, Antony Loebel
Format:	Article
Language:	English
Published:	BMC 2018-04-01
Series:	BMC Health Services Research
Subjects:	Antipsychotic medication Retrospective studies Hospital Schizophrenia
Online Access:	http://link.springer.com/article/10.1186/s12913-018-3020-2

Similar Items

Schizophrenia relapse, patient considerations, and potential role of lurasidone
by: Citrome L
Published: (2016-08-01)

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records
by: Jonathan M. Meyer, et al.
Published: (2017-10-01)

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
by: Greg W. Mattingly, et al.
Published: (2020-05-01)

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
by: Afzal Javed, et al.
Published: (2019-05-01)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
by: Iyo M, et al.
Published: (2021-08-01)

Antipsychotic treatments; Focus on lurasidone
by: Tomiki eSumiyoshi
Published: (2013-08-01)

Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
by: Adriano Aquino, et al.
Published: (2018-05-01)

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia
by: Brian J. Miller, et al.
Published: (2020-10-01)

Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study
by: Berger Ariel, et al.
Published: (2012-08-01)

Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand
by: Boonlue T, et al.
Published: (2016-04-01)

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
by: Philip D. Harvey, et al.
Published: (2016-09-01)

A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia
by: Amrita Prakash Singam, et al.
Published: (2011-01-01)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
by: Hong Jihyung, et al.
Published: (2012-12-01)

Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders
by: Bole Cvetka Bačar, et al.
Published: (2017-03-01)

Suicide in Schizophrenia: An Educational Overview
by: Leo Sher, et al.
Published: (2019-07-01)

THE ROLE OF ATYPICAL ANTIPSYCHOTIC DECREASING AGGRESIVENESS IN SCHIZOPHRENIA
by: Juvita Novia Anggraini Maria
Published: (2013-03-01)

Symptomatic Resolution Among Chinese Patients With Schizophrenia and Associated Factors
by: Cheng-Ta Li, et al.
Published: (2010-05-01)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
by: Davide Amato, et al.
Published: (2019-05-01)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
by: Aubel T
Published: (2021-07-01)

Treatment resistant schizophrenia in Slovenian population
by: Tea Terzić, et al.
Published: (2014-10-01)

The Role of Cytokines in the Pathogenesis of Schizophrenia
by: Bartosz Dawidowski, et al.
Published: (2021-08-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients
by: Yansong Liu, et al.
Published: (2019-04-01)

Antipsychotic medication non-adherence among schizophrenia patients in Central Ethiopia
by: Minale Tareke, et al.
Published: (2018-03-01)

Evaluation of naltrexone augmentation to the antipsychotic drugs on positive and negative symptoms of schizophrenia
by: Javad Setareh, et al.
Published: (2008-01-01)

Altered expression of the DISC1 gene in peripheral blood of patients with schizophrenia
by: Xiaoqian Fu, et al.
Published: (2020-10-01)

Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature
by: Andreea Teodorescu, et al.
Published: (2017-08-01)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
by: Zhang LL, et al.
Published: (2016-01-01)

Transdermal Asenapine in Schizophrenia: A Systematic Review
by: Carrithers B, et al.
Published: (2020-08-01)

Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia
by: Kristian S. Hill, et al.
Published: (2009-04-01)

Regional brain metabolism in schizophrenia: The influence of antipsychotics
by: Seethalakshmi R, et al.
Published: (2007-01-01)

A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics
by: Dinesh Panati, et al.
Published: (2020-01-01)

Comparison of Prescribing Patterns for Typical and Atypical Antipsychotics in Patients with Schizophrenia Before and After the Publication of the Phase I "CATIE" Trial
by: Varga, Ross
Published: (2007)

Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia
by: Banny Silva Barbosa Correia, et al.
Published: (2021-02-01)

Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia
by: Danielle Gouvêa-Junqueira, et al.
Published: (2020-04-01)

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
by: Tamara Melnik, et al.

Association of metabolic syndrome with schizophrenia
by: Sarita Bajaj, et al.
Published: (2013-01-01)

Real-World Functioning in Patients With Schizophrenia: Beyond Negative and Cognitive Symptoms
by: María Paz García-Portilla, et al.
Published: (2021-08-01)

Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2020-10-01)

Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes
by: Alexandre González-Rodríguez, et al.
Published: (2020-08-01)